Chronic Idiopathic Constipation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major chronic idiopathic constipation markets reached a value of US$ 6.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 10.7 Billion by 2034, exhibiting a growth rate (CAGR) of 4.91% during 2024-2034.
The chronic idiopathic constipation market has been comprehensively analyzed in IMARC's new report titled "Chronic Idiopathic Constipation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic idiopathic constipation (CIC) is a type of functional bowel disorder that persists for several months or longer without an apparent underlying cause. This condition is majorly associated with a negative impact on the patient's quality of life, affecting social and professional well-being. The common symptoms of CIC include constipation or difficulty passing stools, straining while defecating, hard and lumpy stools, a feeling of incomplete evacuation following completion, abdominal pain, discomfort, and bloating, excessive flatulence, poorer physical functioning, a decreased perception of health, etc. The diagnosis of this ailment involves a combination of an in-depth medical history, an evaluation of clinical features, and a physical exam. Numerous imaging studies, including magnetic resonance imaging (MRI) scans and anal manometry, are also recommended to confirm a diagnosis. The healthcare provider may perform a colonoscopy, which involves the insertion of a long, flexible tube (colonoscope) into the rectum to visualize the possible cause of the patient's symptoms.
The rising prevalence of numerous associated risk factors, such as reduced colon motility, inadequate fluid and fiber intake in the diet, unhealthy lifestyle habits, pelvic floor dysfunction, etc., is primarily driving the chronic idiopathic constipation market. Furthermore, the increasing cases of visceral sensory abnormalities or alterations in the enteric nervous system that decrease rectal sensation and the need to defecate are also augmenting the market growth. In addition to this, the inflating utilization of wireless capsule endoscopy, a non-invasive diagnostic procedure that helps determine gastrointestinal motility, gastric emptying, colonic and small bowel transit, as well as whole gut transit times, is creating a positive outlook for the market. Moreover, the widespread adoption of stimulant laxatives, including bisacodyl and sodium picosulfate, since they decrease water absorption, stimulate intestinal motility directly, and release prostaglandins that aid in the acceleration of intestinal transit is further bolstering the market growth. Apart from this, the emerging popularity of sacral nerve stimulation to stabilize the normal functioning of the bowel and sphincter muscles in patients who are refractory to pharmacotherapy is expected to drive the chronic idiopathic constipation market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the chronic idiopathic constipation market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic idiopathic constipation and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic idiopathic constipation market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic idiopathic constipation market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic idiopathic constipation market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic idiopathic constipation marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic idiopathic constipation market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic idiopathic constipation market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic idiopathic constipation market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of chronic idiopathic constipation across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of chronic idiopathic constipation by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of chronic idiopathic constipation by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with chronic idiopathic constipation across the seven major markets?
What is the size of the chronic idiopathic constipation patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic idiopathic constipation?
What will be the growth rate of patients across the seven major markets?
Chronic Idiopathic Constipation: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic idiopathic constipation drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic idiopathic constipation market?
What are the key regulatory events related to the chronic idiopathic constipation market?
What is the structure of clinical trial landscape by status related to the chronic idiopathic constipation market?
What is the structure of clinical trial landscape by phase related to the chronic idiopathic constipation market?
What is the structure of clinical trial landscape by route of administration related to the chronic idiopathic constipation market?
The chronic idiopathic constipation market has been comprehensively analyzed in IMARC's new report titled "Chronic Idiopathic Constipation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic idiopathic constipation (CIC) is a type of functional bowel disorder that persists for several months or longer without an apparent underlying cause. This condition is majorly associated with a negative impact on the patient's quality of life, affecting social and professional well-being. The common symptoms of CIC include constipation or difficulty passing stools, straining while defecating, hard and lumpy stools, a feeling of incomplete evacuation following completion, abdominal pain, discomfort, and bloating, excessive flatulence, poorer physical functioning, a decreased perception of health, etc. The diagnosis of this ailment involves a combination of an in-depth medical history, an evaluation of clinical features, and a physical exam. Numerous imaging studies, including magnetic resonance imaging (MRI) scans and anal manometry, are also recommended to confirm a diagnosis. The healthcare provider may perform a colonoscopy, which involves the insertion of a long, flexible tube (colonoscope) into the rectum to visualize the possible cause of the patient's symptoms.
The rising prevalence of numerous associated risk factors, such as reduced colon motility, inadequate fluid and fiber intake in the diet, unhealthy lifestyle habits, pelvic floor dysfunction, etc., is primarily driving the chronic idiopathic constipation market. Furthermore, the increasing cases of visceral sensory abnormalities or alterations in the enteric nervous system that decrease rectal sensation and the need to defecate are also augmenting the market growth. In addition to this, the inflating utilization of wireless capsule endoscopy, a non-invasive diagnostic procedure that helps determine gastrointestinal motility, gastric emptying, colonic and small bowel transit, as well as whole gut transit times, is creating a positive outlook for the market. Moreover, the widespread adoption of stimulant laxatives, including bisacodyl and sodium picosulfate, since they decrease water absorption, stimulate intestinal motility directly, and release prostaglandins that aid in the acceleration of intestinal transit is further bolstering the market growth. Apart from this, the emerging popularity of sacral nerve stimulation to stabilize the normal functioning of the bowel and sphincter muscles in patients who are refractory to pharmacotherapy is expected to drive the chronic idiopathic constipation market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the chronic idiopathic constipation market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic idiopathic constipation and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic idiopathic constipation market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic idiopathic constipation market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic idiopathic constipation market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic idiopathic constipation marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic idiopathic constipation market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic idiopathic constipation market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic idiopathic constipation market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of chronic idiopathic constipation across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of chronic idiopathic constipation by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of chronic idiopathic constipation by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with chronic idiopathic constipation across the seven major markets?
What is the size of the chronic idiopathic constipation patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic idiopathic constipation?
What will be the growth rate of patients across the seven major markets?
Chronic Idiopathic Constipation: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic idiopathic constipation drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic idiopathic constipation market?
What are the key regulatory events related to the chronic idiopathic constipation market?
What is the structure of clinical trial landscape by status related to the chronic idiopathic constipation market?
What is the structure of clinical trial landscape by phase related to the chronic idiopathic constipation market?
What is the structure of clinical trial landscape by route of administration related to the chronic idiopathic constipation market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC IDIOPATHIC CONSTIPATION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHRONIC IDIOPATHIC CONSTIPATION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC IDIOPATHIC CONSTIPATION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 CHRONIC IDIOPATHIC CONSTIPATION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC IDIOPATHIC CONSTIPATION - UNMET NEEDS
10 CHRONIC IDIOPATHIC CONSTIPATION - KEY ENDPOINTS OF TREATMENT
11 CHRONIC IDIOPATHIC CONSTIPATION - MARKETED PRODUCTS
11.1 List of Chronic Idiopathic Constipation Marketed Drugs Across the Top 7 Markets
11.1.1 Linzess (Lenalidomide) - Ironwood Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Motegrity (Prucalopride) - Takeda
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Pizensy (Lactitol) - Sebela Pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Trulance (Plecanatide) - Bausch Health Companies
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Amitiza (Lubiprostone) - Mallinckrodt
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CHRONIC IDIOPATHIC CONSTIPATION - PIPELINE DRUGS
12.1 List of Chronic Idiopathic Constipation Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. CHRONIC IDIOPATHIC CONSTIPATION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC IDIOPATHIC CONSTIPATION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC IDIOPATHIC CONSTIPATION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Idiopathic Constipation - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Idiopathic Constipation - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Idiopathic Constipation - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Idiopathic Constipation - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Idiopathic Constipation - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Idiopathic Constipation - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Idiopathic Constipation - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Idiopathic Constipation - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Idiopathic Constipation - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Idiopathic Constipation - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Idiopathic Constipation - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Idiopathic Constipation - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Idiopathic Constipation - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Idiopathic Constipation - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Idiopathic Constipation - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Idiopathic Constipation - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Idiopathic Constipation - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Idiopathic Constipation - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Idiopathic Constipation - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Idiopathic Constipation - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Idiopathic Constipation - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Idiopathic Constipation - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Idiopathic Constipation - Access and Reimbursement Overview
16 CHRONIC IDIOPATHIC CONSTIPATION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC IDIOPATHIC CONSTIPATION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC IDIOPATHIC CONSTIPATION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC IDIOPATHIC CONSTIPATION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHRONIC IDIOPATHIC CONSTIPATION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC IDIOPATHIC CONSTIPATION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 CHRONIC IDIOPATHIC CONSTIPATION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC IDIOPATHIC CONSTIPATION - UNMET NEEDS
10 CHRONIC IDIOPATHIC CONSTIPATION - KEY ENDPOINTS OF TREATMENT
11 CHRONIC IDIOPATHIC CONSTIPATION - MARKETED PRODUCTS
11.1 List of Chronic Idiopathic Constipation Marketed Drugs Across the Top 7 Markets
11.1.1 Linzess (Lenalidomide) - Ironwood Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Motegrity (Prucalopride) - Takeda
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Pizensy (Lactitol) - Sebela Pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Trulance (Plecanatide) - Bausch Health Companies
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Amitiza (Lubiprostone) - Mallinckrodt
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CHRONIC IDIOPATHIC CONSTIPATION - PIPELINE DRUGS
12.1 List of Chronic Idiopathic Constipation Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. CHRONIC IDIOPATHIC CONSTIPATION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC IDIOPATHIC CONSTIPATION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC IDIOPATHIC CONSTIPATION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Idiopathic Constipation - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Idiopathic Constipation - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Idiopathic Constipation - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Idiopathic Constipation - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Idiopathic Constipation - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Idiopathic Constipation - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Idiopathic Constipation - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Idiopathic Constipation - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Idiopathic Constipation - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Idiopathic Constipation - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Idiopathic Constipation - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Idiopathic Constipation - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Idiopathic Constipation - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Idiopathic Constipation - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Idiopathic Constipation - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Idiopathic Constipation - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Idiopathic Constipation - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Idiopathic Constipation - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Idiopathic Constipation - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Idiopathic Constipation - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Idiopathic Constipation - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Idiopathic Constipation - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Idiopathic Constipation - Access and Reimbursement Overview
16 CHRONIC IDIOPATHIC CONSTIPATION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC IDIOPATHIC CONSTIPATION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC IDIOPATHIC CONSTIPATION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
